Journal Article Summary
This article investigates the effectiveness and safety of switching from infliximab to adalimumab in patients with rheumatoid arthritis (RA). Understanding how patients respond to different treatments is crucial, especially for those who may not tolerate one medication well. This study is significant as it provides insights into alternative treatment options for RA patients who have had to discontinue infliximab, a common therapy for this chronic condition.
The study involved 49 patients with RA, divided into two groups: 24 patients who switched from infliximab to adalimumab and 25 patients who started adalimumab without prior anti-tumor necrosis factor (TNF) treatment. Both groups received adalimumab injections every two weeks for a year. The researchers measured disease activity and clinical response using specific scoring systems. The results showed that both groups experienced similar levels of improvement, with about 75% of switchers and 76% of controls meeting the criteria for a significant clinical response after 12 months.
While the study provides valuable information, it has limitations, including a small sample size and a relatively short follow-up period. Additionally, some patients in both groups discontinued treatment due to side effects or lack of effectiveness, highlighting the importance of monitoring for adverse reactions. Patients considering a switch in their RA treatment should discuss these findings with their healthcare provider to weigh the benefits and risks based on their individual health needs.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Nikas S N, Voulgari P V, Alamanos Y, Papadopoulos C G, Venetsanopoulou A I, Georgiadis A N, Drosos A A. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Annals of the Rheumatic Diseases 2006. DOI: 10.1136/ard.2005.039099. PMID: 15975964. PMCID: PMC1798023.
Featured Pill Pals Product
Adalimumab-ADAZ 40 MG / 0.4 ML Auto Injector x 2 Syringes --- Sandoz Brand --- Bioequivalent to Humira
Adalimumab-ADAZ 40 MG / 0.4 ML Auto Injector x 2 Syringes --- Sandoz Brand --- Bioequivalent to Humira is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription may be required.
